[Human recombinant erythropoietin in the treatment of anemia in obstetric-gynecologic patients. Evaluation of such treatment as an alternative to blood transfusion]

Minerva Ginecol. 1996 Mar;48(3):115-8.
[Article in Italian]

Abstract

The authors introduce the subject with physiological comments regarding the ability of r-HuEP to stimulate erythropoietic bone marrow, underlining the need for other molecules to backup the therapy (vitamin B12, folic acid and iron). Subsequently, and in the light of this introduction, they outline the indications for r-HuEPO treatment in specialist fields and the relative contraindications. They then report the results obtained in a group of 24 patients with the relevant indications receiving subcutaneous treatment on alterate days with r-HuEPO in fials of 4000 IU/ml. Basal hemoglobin levels were 6-8 g and treatment was continued until levels of around 10-11 g were reached; tolerance was good in both gynecological and obstetric patients.

Publication types

  • Clinical Trial
  • Clinical Trial, Phase II
  • Comparative Study
  • English Abstract
  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Anemia / drug therapy*
  • Anemia / etiology
  • Blood Transfusion
  • Dose-Response Relationship, Drug
  • Drug Therapy, Combination
  • Erythropoietin / therapeutic use*
  • Female
  • Ferrous Compounds / therapeutic use
  • Folic Acid / therapeutic use
  • Genital Diseases, Female / blood
  • Genital Diseases, Female / complications*
  • Genital Diseases, Female / drug therapy
  • Humans
  • Pregnancy
  • Puerperal Disorders / blood
  • Puerperal Disorders / complications*
  • Puerperal Disorders / drug therapy
  • Vitamin B 12 / therapeutic use

Substances

  • Ferrous Compounds
  • Erythropoietin
  • Folic Acid
  • Vitamin B 12